Adcendo – Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
Copenhagen, Denmark, April 11th, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, is pleased to announce that a poster presentation will be provided on data of uPARAP targeting Antibody-Drug Conjugates in osteosarcoma preclinical xenograft models at the ongoing American Association for Cancer Research (AACR) Annual Meeting, held in New Orleans from April 8-13, 2022.